COPD exacerbations are serious and often require hospitalization. Instead of adding an OTC medication on your own, which is unlikely to be effective and may be dangerous, ask your healthcare ...

2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Despite its established use in other conditions, the antibody is not yet approved for COPD treatment in any nation ... in individuals with a history of exacerbations and elevated counts of ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Dupixent for the treatment of COPD has been approved ... Patients with COPD and elevated eosinophils have an increased risk of exacerbations and COPD-related hospitalizations within a year.